title: Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings.
abstract: Although only poorly documented, it can be assumed that intensive antibiotic treatments of chronic lung infections in patients with cystic fibrosis (CF) also affect the diversity and metabolic functioning of the gastrointestinal microbiota and potentially lead to a state of dysbiosis. A better knowledge of the differences in gut microbiota composition and stability between patients with CF and healthy subjects could lead to optimization of current antibiotic therapies and/or development of add-on therapies. Using conventional culturing and population fingerprinting by denaturing gradient gel electrophoresis (DGGE) of 16S rRNA amplicons, we compared the predominant fecal microbiota of 21 patients with CF and 24 healthy siblings in a cross-sectional study. General medium counts, as well as counts on media specific for lactic acid bacteria, clostridia, Bifidobacterium spp., Veillonella spp., and Bacteroides-Prevotella spp., were consistently higher in sibling samples than in CF samples, whereas the reverse was found for enterobacterial counts. DGGE fingerprinting uncovered large intersubject variations in both study groups. On the other hand, the cross-sectional data indicated that the predominant fecal microbiota of patients and siblings had comparable species richness. In addition, a longitudinal study was performed on 7 or 8 consecutive samples collected over a 2-year period from two patients and their respective siblings. For these samples, DGGE profiling indicated an overall trend toward lower temporal stability and lower species richness in the predominant fecal CF microbiota. The observed compositional and dynamic perturbations provide the first evidence of a general dysbiosis in children with CF compared to their siblings.
authors.affiliation: Faculty of Sciences, Laboratory of Microbiology, K. L. Ledeganckstraat 35, 9000 Ghent, Belgium. Gwen.Duytschaever@Ugent.be
authors.forename: Gwen
authors.initials: G
authors.lastname: Duytschaever
authors.forename: Geert
authors.initials: G
authors.lastname: Huys
authors.forename: Maarten
authors.initials: M
authors.lastname: Bekaert
authors.forename: Linda
authors.initials: L
authors.lastname: Boulanger
authors.forename: Kris
authors.initials: K
authors.lastname: De Boeck
authors.forename: Peter
authors.initials: P
authors.lastname: Vandamme
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001419:Bacteria / Q000145:classification* / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D044822:Biodiversity; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000235:genetics; D004275:DNA, Ribosomal / Q000235:genetics; D058645:Denaturing Gradient Gel Electrophoresis; D005243:Feces / Q000382:microbiology*; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000382:microbiology; D006801:Humans; D008137:Longitudinal Studies; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D035781:Siblings
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S